Logo Image
Back

Evolution of Precision Medicine in Non–Small Cell Lung Cancer

Evolution of Precision Medicine in Non–Small Cell Lung Cancer

Experts discuss advancements in the development of targeted agents in oncogene-driven non–small cell lung cancer, highlight the results from key clinical trials presented at the American Society of Clinical Oncology 2021 Annual Meeting, and provide insights on how these findings may support treatment decision making in an era of precision medicine.

Evolution of Precision Medicine in Non–Small Cell Lung Cancer

Episodes

All
All

EP. 1: NSCLC: ADAURA Trial Results

ByBen Levy, MD, The Johns Hopkins University School of Medicine,Melissa Johnson, MD, Tennessee Oncology,Edward Kim, MD, MBA, City of Hope National Medical Center,Jacob Sands, MD, Dana-Farber Cancer Institute,Alexander Spira, MD, PhD, FACP, Virginia Cancer Specialists, US Oncology

Ben Levy, MD, leads a discussion about the evolution of precision medicine in non–small cell lung cancer (NSCLC) beginning with an overview of the results from the ADAURA trial.

EP. 5: Implications of Novel NSCLC Targeted Therapies

ByBen Levy, MD, The Johns Hopkins University School of Medicine,Melissa Johnson, MD, Tennessee Oncology,Edward Kim, MD, MBA, City of Hope National Medical Center,Jacob Sands, MD, Dana-Farber Cancer Institute,Alexander Spira, MD, PhD, FACP, Virginia Cancer Specialists, US Oncology

An expert in non–small cell lung cancer (NSCLC) provides an overview of recent data presented at the American Society of Clinical Oncology 2021 annual meeting to treat MET exon 14 mutations.

EP. 6: Novel Therapies for NSCLC

ByBen Levy, MD, The Johns Hopkins University School of Medicine,Melissa Johnson, MD, Tennessee Oncology,Edward Kim, MD, MBA, City of Hope National Medical Center,Jacob Sands, MD, Dana-Farber Cancer Institute,Alexander Spira, MD, PhD, FACP, Virginia Cancer Specialists, US Oncology

Edward Kim, MD, MBA, summarizes recent data for HER2-mutated in non–small cell lung cancer (NSCLC) presented at the American Society of Clinical Oncology 2021 annual meeting.

EP. 7: NSCLC: EGFR Exon 20 Insertion Treatment Options

ByBen Levy, MD, The Johns Hopkins University School of Medicine,Melissa Johnson, MD, Tennessee Oncology,Edward Kim, MD, MBA, City of Hope National Medical Center,Jacob Sands, MD, Dana-Farber Cancer Institute,Alexander Spira, MD, PhD, FACP, Virginia Cancer Specialists, US Oncology

Experts provide an overview of treatment options for exon 20 insertion EGFR mutations in non–small cell lung cancer (NSCLC) and trial updates presented at the American Society of Clinical Oncology 2021 annual meeting .

EP. 8: ASCO 2021: New Data for NSCLC Treatment Options

ByBen Levy, MD, The Johns Hopkins University School of Medicine,Melissa Johnson, MD, Tennessee Oncology,Edward Kim, MD, MBA, City of Hope National Medical Center,Jacob Sands, MD, Dana-Farber Cancer Institute,Alexander Spira, MD, PhD, FACP, Virginia Cancer Specialists, US Oncology

Jacob Sands, MD, reviews data regarding the investigational oral EGFR inhibitor DZD9008 that were presented at the American Society of Clinical Oncology (ASCO) 2021 annual meeting for the treatment of non–small cell lung cancer (NSCLC).

EP. 9: Recent FDA-Approvals: KRAS G12C-Mutated NSCLC

ByBen Levy, MD, The Johns Hopkins University School of Medicine,Melissa Johnson, MD, Tennessee Oncology,Edward Kim, MD, MBA, City of Hope National Medical Center,Jacob Sands, MD, Dana-Farber Cancer Institute,Alexander Spira, MD, PhD, FACP, Virginia Cancer Specialists, US Oncology

An overview of new data presented at the American Society of Clinical Oncology 2021 annual meeting for KRAS G12C-mutated non–small cell lung cancer (NSCLC).

EP. 11: Recent FDA-Approvals: HER2-Mutated NSCLC

ByBen Levy, MD, The Johns Hopkins University School of Medicine,Melissa Johnson, MD, Tennessee Oncology,Edward Kim, MD, MBA, City of Hope National Medical Center,Jacob Sands, MD, Dana-Farber Cancer Institute,Alexander Spira, MD, PhD, FACP, Virginia Cancer Specialists, US Oncology

Edward Kim, MD, MBA, summarizes recent data for HER2-mutated in non–small cell lung cancer (NSCLC) presented at the American Society of Clinical Oncology 2021 annual meeting.

EP. 12: Recent FDA-Approvals: MET Exon 14 Mutations in NSCLC

ByBen Levy, MD, The Johns Hopkins University School of Medicine,Melissa Johnson, MD, Tennessee Oncology,Edward Kim, MD, MBA, City of Hope National Medical Center,Jacob Sands, MD, Dana-Farber Cancer Institute,Alexander Spira, MD, PhD, FACP, Virginia Cancer Specialists, US Oncology

An expert in non–small cell lung cancer (NSCLC) provides an overview of recent data presented at the American Society of Clinical Oncology 2021 annual meeting to treat MET exon 14 mutations.

EP. 13: RET-Fusions in NSCLC: Updates From ASCO

ByBen Levy, MD, The Johns Hopkins University School of Medicine,Melissa Johnson, MD, Tennessee Oncology,Edward Kim, MD, MBA, City of Hope National Medical Center,Jacob Sands, MD, Dana-Farber Cancer Institute,Alexander Spira, MD, PhD, FACP, Virginia Cancer Specialists, US Oncology

An overview of the RET-fusion data updates that were presented at the American Society of Clinical Oncology (ASCO) 2021 annual meeting in non–small cell lung cancer (NSCLC).

EP. 14: ALK-Rearranged NSCLC: Updates From ASCO

ByBen Levy, MD, The Johns Hopkins University School of Medicine,Melissa Johnson, MD, Tennessee Oncology,Edward Kim, MD, MBA, City of Hope National Medical Center,Jacob Sands, MD, Dana-Farber Cancer Institute,Alexander Spira, MD, PhD, FACP, Virginia Cancer Specialists, US Oncology

A summary of recent data that were presented at the American Society of Clinical Oncology (ASCO) 2021 annual meeting for ALK-rearranged non–small cell lung cancer (NSCLC).

EP. 16: ROS1-Rearranged NSCLC: Updates FromASCO

ByBen Levy, MD, The Johns Hopkins University School of Medicine,Melissa Johnson, MD, Tennessee Oncology,Edward Kim, MD, MBA, City of Hope National Medical Center,Jacob Sands, MD, Dana-Farber Cancer Institute,Alexander Spira, MD, PhD, FACP, Virginia Cancer Specialists, US Oncology

An overview of TKIs in ROS1-rearranged non–small cell lung cancer (NSCLC) and updated trial results that were presented at the American Society of Clinical Oncology (ASCO) 2021 annual meeting.

EP. 17: NSCLC: Overcoming Challenges

ByBen Levy, MD, The Johns Hopkins University School of Medicine,Melissa Johnson, MD, Tennessee Oncology,Edward Kim, MD, MBA, City of Hope National Medical Center,Jacob Sands, MD, Dana-Farber Cancer Institute,Alexander Spira, MD, PhD, FACP, Virginia Cancer Specialists, US Oncology

Oncology experts provide insight on screening methods available and discuss strategies that may address challenges in identification of targetable mutations/tumor profiles in non–small cell lung cancer (NSCLC).